Table 3

Growth behavior and drug sensitivity of HOC xenografts transplanted in nude mice

Tumor modelGrowth siteDoubling time ± SD (s.c. tumors)MST (range) (i.p. tumors)Paclitaxel sensitivitya
1A9i.p./s.c.4 ± 238 (23–51)++++
HOC76i.p./s.c.10.2 ± 1.967 (46–169)+
HOC79i.p./s.c.12.5 ± 2.571 (38–96)+
HOC84s.c.12 ± 3n.t.b++++
HOC94/2s.c.10 ± 2n.t.+++
HOC106s.c.12.2 ± 2n.t.n.t.
HOC107s.c.37.7 ± 10n.t.+++
HOC109s.c.8.2 ± 2n.t.+++
HOC110i.p.n.t.92 (90–108)+
HOC119s.c.7.7 ± 3.6n.t.++
HOC130i.p.n.t.50 (36–67)
MNB-PTX1s.c.8 ± 2n.t.
MNB-PTX2s.c.11 ± 2.5n.t.+
  • a 20 mg/kg paclitaxel (Q4 × 3, i.v.); treatments started at 1/4 MST for i.p. tumors and at 150 ± 50 g of weight for s.c. tumors. Criteria of antitumor activity: −, inactive (ILS < 40%; T/C > 50%); +, minimal activity (40% < ILS < 75%; T/C < 50%); ++, moderate activity (75% < ILS < 100%; T/C < 40%); +++, good activity (100% < ILS < 150%; T/C < 25%); and ++++, optimal activity (ILS > 150% or complete remissions; T/C < 10%).

  • b n.t., not tested.